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Abstract
Background: Gossypol, a naturally occurring polyphenolic compound has been identified as a small molecule inhibitor
of anti-apoptotic Bcl-2 family proteins. It induces apoptosis in a wide range of tumor cell lines and enhances
chemotherapy- and radiation-induced cytotoxicity both in vitro and in vivo. Bcl-2 and related proteins are important
inhibitors of apoptosis and frequently overexpressed in human tumors. Increased levels of these proteins confer radio-
and chemoresistance and may be associated with poor prognosis. Consequently, inhibition of the anti-apoptotic functions
of Bcl-2 family members represents a promising strategy to overcome resistance to anticancer therapies.
Methods: We tested the effect of (-)-gossypol, also denominated as AT-101, radiation and the combination of both on
apoptosis induction in human leukemic cells, Jurkat T and U937. Because activation of the SAPK/JNK pathway is
important for apoptosis induction by many different stress stimuli, and Bcl-XL is known to inhibit activation of SAPK/JNK,
we also investigated the role of this signaling cascade in AT-101-induced apoptosis using a pharmacologic and genetic
approach.
Results: AT-101 induced apoptosis in a time- and dose-dependent fashion, with ED50 values of 1.9 and 2.4 μM in Jurkat
T and U937 cells, respectively. Isobolographic analysis revealed a synergistic interaction between AT-101 and radiation,
which also appeared to be sequence-dependent. Like radiation, AT-101 activated SAPK/JNK which was blocked by the
kinase inhibitor SP600125. In cells overexpressing a dominant-negative mutant of c-Jun, AT-101-induced apoptosis was
significantly reduced.
Conclusion: Our data show that AT-101 strongly enhances radiation-induced apoptosis in human leukemic cells and
indicate a requirement for the SAPK/JNK pathway in AT-101-induced apoptosis. This type of apoptosis modulation may
overcome treatment resistance and lead to the development of new effective combination therapies.
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Modulation of apoptosis sensitivity has emerged as a
promising strategy to increase tumor cell kill [1]. Apopto-
sis or programmed cell death is a characteristic mode of
cell destruction and represents an important regulatory
mechanism for removing abundant and unwanted cells
during embryonic development, growth, differentiation
and normal cell turnover. Radiation and most chemother-
apeutic drugs induce apoptosis in a time- and dose-
dependent fashion. Failure to eliminate cells that have
been exposed to mutagenic agents by apoptosis has been
associated with the development of cancer and resistance
to anticancer therapy. Indeed, several oncogenes mediate
their effects by interfering with apoptotic signaling or by
modulation of the apoptotic threshold. Bcl-2 and Bcl-XL
are important inhibitors of apoptosis and frequently over-
expressed in a variety of human tumors [2-7]. Increased
levels of Bcl-2 and Bcl-XL have been associated with radio-
and chemoresistance and poor clinical outcome in vari-
ous types of cancer [8-12]. In fact, among all genes studied
to date in the NCI's panel of 60 human tumor cell lines,
Bcl-XL shows one of the strongest correlations with resist-
ance to cytotoxic anticancer agents [13]. Therefore, inhibi-
tion of anti-apoptotic Bcl-2 family members represents an
appealing strategy to overcome resistance to conventional
anticancer therapies. In recent years, several agents target-
ing the Bcl-2 family proteins have been developed [14]
Gossypol has been identified as a potent inhibitor of Bcl-
XL and, to a lesser extent, of Bcl-2 [15]. It is a naturally
occurring polyphenolic compound derived from cotton-
seed and was initially evaluated as an anti-fertility agent.
Gossypol induces apoptosis in tumor cells with high Bcl-
XL and/or Bcl-2 expression levels, leaving normal cells
with low expression levels (e.g. fibroblasts, keratinocytes)
relatively unaffected [16]. Racemic (±)-gossypol is com-
posed of 2 enantiomers: (+)-gossypol and (-)-gossypol
(Fig. 1). (-)-gossypol, also denoted as AT-101, binds with
high affinity to Bcl-XL, Bcl-2 and Mcl-1 [17] and is a more
potent inducer of apoptosis than (+)-gossypol [15,16,18].
AT-101-induced cell death is associated with apoptosis
hallmarks like Bak activation, cytochrome c release and
effector caspase 3 cleavage [19].
Few studies have addressed the effect of gossypol in com-
bination with chemo- or radiotherapy [20-25]. In vitro,
enhanced apoptosis and reduced clonogenicity was
observed when AT-101 was combined with radiation in a
prostate cancer line [22], while CHOP chemotherapy sig-
nificantly enhanced AT-101-induced cytotoxicity in lym-
phoma cells [21]. Recent studies in multiple myeloma cell
lines demonstrated synergistic toxicity with dexametha-
sone [25]. In head and neck squamous carcinoma cell
lines the combination of stat3 decoy and AT-101 as well
as the triple combination of erlotinib, stat3 decoy and AT-
101 showed significant enhancement of growth inhibi-
tion [26]. Also in vivo the combined treatment of AT-101
with radiation [22] or chemotherapy [21] resulted in
superior anti-tumor efficacy compared to single agent
treatment. The interaction between radiation and AT-101
appeared to be sequence-dependent with radiation "sen-
sitizing" the cells for AT-101, but not vice versa [22].
Activation of SAPK/JNK has been shown to play an impor-
tant role in apoptosis induction by many stimuli, includ-
ing radiation and chemotherapeutic drugs [27,28]. This,
together with the observation that one of the major targets
of AT-101, Bcl-XL, inhibits SAPK/JNK action [29] stimu-
lated us to investigate whether gossypol activates this
pathway and whether this contributes to the pro-apop-
totic effect of this novel compound.
In the present study, we describe the apoptotic effect of
ionizing radiation and AT-101 in the human leukemic cell
lines U937 and Jurkat T. We determined whether the com-
bination of both treatment modalities would induce
higher levels of apoptosis than after single agent treatment
and characterized the type of interaction. We also tested
the hypothesis that activation of the SAPK/JNK pathway is
important for AT-101-induced apoptosis in these cell sys-
tems.
Methods
Reagents
AT-101 was provided by Ascenta Therapeutics, Inc. (Mal-
vern, PA, USA). (±)-Gossypol was purchased from Sigma-
Aldrich. Stock solutions were prepared in dimethylsulfox-
ide to a concentration of 20 mM and stored at 4°C. Prior
to use an aliquot was diluted in Dulbecco's modified
Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA).
Phospho-SAPK/JNK (Thr183/Tyr185) monoclonal anti-
body was from Cell Signaling Technology, Inc. The SAPK/
JNK inhibitor anthrax(1,9-cd)pyrazol-692H)-one
(SP600125) [30] was obtained from BIOMOL Research
Laboratories (Plymouth Meeting, PA, USA) and dissolved
in dimethylsulfoxide.Chemical structure of the (-) and (+) enantiomer of gossypolFigure 1
Chemical structure of the (-) and (+) enantiomer of 
gossypol.
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Human monoblastic leukemia cells (U937) and the
human T lymphoid leukemic Jurkat cell line (J16, kindly
provided by Prof. J. Borst, The Netherlands Cancer Insti-
tute, Amsterdam), both expressing Bcl-XL, Bcl-2 and Mcl-
1 (not shown) were grown at a density between 0.1 × 106
and 1 × 106 cells/ml respectively in RPMI and Iscove's
modified Dulbecco's medium (Invitrogen, Carlsbad, CA,
USA, Paisley, Scotland), 8% heat-inactivated fetal calf
serum, glutamine (2 mM), penicillin (50 U/ml) and strep-
tomycin (50 μg/ml). U937 cells stably transfected with
TAM-67 (U937/TAM-67 cells; a kind gift from dr. M.J. Bir-
rer, National Cancer Institute, Rockville, Maryland) [31].
In selected experiments 2 human head and neck squa-
mous cell carcinoma lines were used (VU-SCC-OE and
UM-SCC-11B). These cell lines were grown in DMEM sup-
plemented with 8% heat-inactivated fetal calf serum,
glutamine (2 mM), penicillin (50 U/ml) and streptomy-
cin (50 μg/ml). For irradiation experiments, cells were
exposed to gamma rays from a 137Cs radiation source
(Von Gahlen B.V., Didam, The Netherlands) at an
absorbed dose rate of approximately 1 Gy/min. Control
cells were sham-irradiated.
Apoptosis assays
Apoptosis was determined by either staining with the
DNA-binding fluorochrome bisbenzimide (Hoechst
33258, Sigma) to detect morphological nuclear changes
or by propidium iodide staining and FACScan analysis to
determine the percentage of subdiploid apoptotic nuclei.
For the bisbenzimide staining, cells were washed once
with PBS and resuspended in 50 μl of 3.7% paraformalde-
hyde. After 10 min at room temperature, the fixative was
removed and the cells were resuspended in 15 μl of PBS
containing 16 μg/ml bisbenzimide. Following 15 min
incubation, a 10 μl aliquot was placed on a glass slide, and
500 cells per slide were scored in duplicate for the inci-
dence of apoptotic nuclear changes under a Olympus
AH2-RFL fluorescence microscope using a UV1 exciter fil-
ter. For the propidium iodide staining, cells were seeded
at 2 × 106 cells/ml, 200 μl/well in round-bottomed, 96-
well microtiter plates. Cells were lysed in 200 μl Nicoletti
Buffer (0.1% sodium citrate, 0.1% Triton X-100, and 50
μg/ml propidium iodide) and the percentage apoptotic
nuclei, recognized by their subdiploid DNA content, was
determined on a FACScan (Becton Dickinson, San Jose,
CA) using Lysys II software.
MTT assay
Cells were grown and treated in 96 well flat-bottomed
plates. Cell survival was measured by spectrophotometri-
cal quantification of the formation of blue formazan crys-
tals which are formed when mitochondrial
dehydrogenases in viable cells reduce 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Sigma). To this end, treated cells were supplemented with
20 μl of MTT solution (5 mg/ml). After 15-30 min of incu-
bation at 37°C the plates were centrifuged and the super-
natant discarded. Formazan crystals were dissolved in 100
μl DMSO. Absorbance at 595 nm was measured using a
Victor 2 absorbance reader (Perkin Elmer GMI, Inc, MN,
USA).
Western blotting
Western blot analysis was performed to detect activated
SAPK/JNK. Cells were washed, replenished with serum
free medium and left overnight. Subsequently, the cul-
tures were treated with increasing doses of radiation and/
or AT-101, washed and lysed in Triton lysis buffer (20 mM
HEPES (pH 7.4), 2 mM EGTA, 50 mM, β-glycerophos-
phate, 1% Triton X-100, 2.5 mM MgCl2, 1 mM NA3VO4, 5μM leupeptin, 2.5 μM aprotinin and 400 μM phenylmeth-
ylsulfonyl fluoride) on ice for 15 min. Lysates were clari-
fied by centrifuging for 10 min at 3000 rpm, normalized
for protein content and 80 μg of total lysate was loaded on
Invitrogen 4-12% acrylamide NuPAGE novex bis-tris gels.
Separated proteins were transferred to nitrocellulose
membranes and blocked for 1 h with 5% (w/v) Nutrilon
Premium (Nutricia Zoetermeer, The Netherlands) in TBS-
T. Blots were probed with SAPK/JNK monoclonal anti-
body (1:500) in 5% Nutrilon in TBS-T. Control blots were
probed with total SAPK/JNK polyclonal antibody
(1:1000) in 1% Nutrilon in TBS-T. After secondary horse-
radish peroxidase-conjugated antibody incubation, pro-
teins were detected using the ECL detection system (GE
Healthcare, Buckinghamshire, UK) and exposed to Amer-
sham Hyperfilm MP (GE Healthcare, Buckinghamshire,
UK).
Statistical analyses
To characterize the interaction between ionizing radiation
and gossypol the combination index (CI) was calculated
and isobolographic analysis was performed. The combi-
nation index was calculated according to the classic isobo-
logram equation described by Chou and Talalay [32]:
In this equation, (Dx)1 and (Dx)2 represent the doses Dx of
compounds 1 and 2 alone required to produce an effect,
and (D)1 and (D)2 represent isoeffective doses D when
compounds 1 and 2 are given simultaneously. The combi-
nation index can either indicate additivity (CI = 1), syner-
gism (CI < 1) or antagonism (CI > 1). For isobolographic
analysis, full dose response curves of both gossypol and
radiation were generated using Graph Pad Prism 4.0 soft-
ware. From each combination effect classic isobolograms
were constructed [33]. A combination point below the
area of additivity indicated a synergistic interaction
between both stimuli.
CI D D D Dx x= +( ) /( ) ( ) /( )1 1 2 2Page 3 of 10
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Radiation and gossypol induce apoptosis
In both U937 and Jurkat T cells, radiation induced a time-
and dose-dependent increase in apoptosis, measured by
bisbenzimide staining and FACScan analysis, as reported
previously [27,34,35]. The earliest morphological nuclear
changes characteristic for apoptosis were detected after 6
h (not shown). Fig. 2A, B shows the dose-dependency of
radiation-induced apoptosis in the two cell lines; ED50
values at t = 24 h are presented in Table 1.
Like radiation, AT-101 induced typical morphological fea-
tures of apoptosis in a time- and dose-dependent fashion
(Fig. 2C, D). As expected, AT-101 was more potent than
the racemic mixture, which is reflected in the difference of
their respective ED50 values (Table 1). AT-101-induced
apoptosis was observed from 8 h onwards. Both radia-
tion- and AT-101-induced apoptosis was fully inhibited
by the pan-caspase inhibitor Z-VAD (data not shown).
Interaction between radiation and AT-101 is synergistic 
and sequence-dependent
To test the combined effect of both modalities, U937 and
Jurkat T cells were irradiated with increasing doses of
gamma rays (0-32 Gy) and 24 h later treated with different
concentrations of AT-101 (0-10 μM). At various time
points up to 24 h after treatment with AT-101, apoptosis
was determined by propidium iodide staining and FACS-
can analysis. The combination of radiation and AT-101
induced more apoptosis than radiation alone and
exceeded the sum of the effects caused by the single agent
treatments (Fig. 3A). To characterize the type of interac-
tion between both treatment modalities, the Combina-
tion Indices were calculated and isobolographic analyses
were performed. For these calculations data from full
Dose-dependent induction of apoptosis by radiation (A, B) and AT-101 (C, D) in human leukemic U937 (A, C) and Jurkat T cell  (B, D)Figure 2
Dose-dependent induction of apoptosis by radiation (A, B) and AT-101 (C, D) in human leukemic U937 (A, C) 
and Jurkat T cells (B, D). Apoptosis was quantified by FACScan analysis at t = 24 h after treatment. Data are presented as 
mean values (± SD) from 3 independent experiments. Inserts in C and D show the time-dependency of AT-101.
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clear synergistic interaction between radiation and AT-
101, as illustrated by a Combination Index of 0.42 and a
combined effect that is projected below the area of addi-
tivity in the isobologram (Fig. 3B).
To determine whether the observed combined effect was
sequence-dependent as shown by others [22], sequential
treatment (radiation followed by AT-101) was compared
with concurrent delivery. As shown in Fig. 3C only when
radiation was applied prior to AT-101 treatment, supra-
additive levels of apoptosis were found. The interval
Table 1: ED50 values for radiation and gossypol in human 
leukemic cells
U937 Jurkat T
Radiation (Gy) 21.6 12.6
AT-101 (μM) 2.4 1.9
(±)-Gossypol (μM) 5.8 2.4
Values are derived from full dose-response curves for each stimulus 
at t = 24 h; data are mean values from 2 independent experiments.
Synergistic and sequence-dependent interaction between radiation and AT-101 in U937 cellsFigu e 3
Synergistic and sequence-dependent interaction between radiation and AT-101 in U937 cells. A: The combina-
tion of radiation and AT-101 induces more apoptosis than the sum of the effects caused by the single agent treatment. Hatched 
bars represent the apoptotic effect by AT-101 alone (0-2 μM); black bars represent the combined effect with radiation (8 Gy). 
B: Isobolographic analysis of the combined effect of 40.6% apoptosis (* in A) induced by 0.4 μM AT-101 and 8 Gy radiation. 
The combination point is projected below the area of additivity, indicating synergy. The combination index for this point: CI = 
0.42. C: Sequence-dependency of radiation and AT-101. Radiation (6 Gy) and AT-101 (1 μM) were either applied concurrently 
(hatched bars) or sequentially (AT-101 24 h after radiation; black bars). Apoptosis was analyzed at t = 24 h after AT-101. D: 
MTT cell viability assays in Jurkat T and U937 cells. AT-101 was added at the indicated concentrations (solid lines); radiation 
was dosed at 8 Gy (dashed line). Viability was determined at t = 48 h after radiation (i.e. 24 h after AT-101). Data presented in 
A, C and D are mean values (± SD) from 2 independent experiments.
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Radiation Oncology 2009, 4:47 http://www.ro-journal.com/content/4/1/47between both modalities should at least be 16 h (not
shown). In contrast, concurrent treatment did not result
in significant interaction which is in agreement with pre-
vious observations [22].
In addition, the effect of AT-101 and radiation on cell via-
bility was measured using the MTT assay under conditions
where we showed apoptosis induction to be synergistic.
Cells were first irradiated and 24 h later treated with AT-
101. Cell viability was measured another 24 h later. As
shown in Fig. 3D, AT-101 induced in a dose-dependent
loss of viability, but did not further reduce cell survival
after radiation.
Gossypol and radiation activate the SAPK/JNK pathway
Because SAPK/JNK-mediated signaling plays an important
role in radiation-, chemotherapy- and environmental
stress-induced apoptosis [27,34], we tested whether gos-
sypol also activates this signaling pathway. As shown in
Fig. 4A and consistent with the apoptosis-inducing capac-
ity, AT-101 is a more potent activator of SAPK/JNK than
racemic gossypol at equimolar concentrations. SAPK/JNK
is activated by AT-101 in a dose- and time-dependent
manner (Fig. 4B and 4C) in a variety of human tumor cell
lines, including leukemic (U937, Jurkat T) and carcinoma
cells (VU-SCC-OE, UM-SCC-11B). As illustrated in Fig.
4C, the kinetics of AT-101-induced SAPK/JNK activation
varied among these different cell lines. The earliest
Gossypol and radiation activate the SAPK/JNK pathwayFigure 4
Gossypol and radiation activate the SAPK/JNK pathway. A: AT-101 is a stronger activator of SAPK/JNK than racemic 
(±)-gossypol. U937 cells were treated with equimolar concentrations of AT-101 (5 μM) and SAPK/JNK activation was analyzed 
at t = 2 h. (Abbreviations: C = control; AT = AT-101; ± =(±)-gossypol). B: Dose-dependent SAPK/JNK activation in U937 
(upper panel) and Jurkat T cells (lower panel). Cells were treated with indicated concentrations of AT-101 and SAPK/JNK acti-
vation was analyzed at t = 2 h. C: Kinetics of 5 μM AT-101-induced SAPK/JNK in human leukemic (U937 and Jurkat T) and car-
cinoma cells (VU-SCC-OE and UM-SCC-11B). D: Radiation (8 Gy) induces a time-dependent SAPK/JNK activation in Jurkat T 
cells (upper panel). In U937 cells, the combination of AT-101 (AT; 5 μM) and radiation (RT; 10 Gy) induces a stronger activa-
tion of SAPK/JNK at t = 2 h than single modality treatment (lower panel).
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Fig. 4D shows the time-dependent activation of SAPK/
JNK by radiation in Jurkat T cells and illustrates the
strongly enhanced SAPK/JNK response after combined
treatment with radiation and AT-101 in U937 cells.
To assess the role of the SAPK/JNK pathway in AT-101-
induced apoptosis, we used the kinase inhibitor
SP600125 [30] and the c-Jun dominant-negative deletion
mutant TAM-67 [31] in U937 cells. As shown in Fig. 5A,
SP600125 inhibited AT-101-induced SAPK/JNK activa-
tion in both cell types studied, while the compound itself
had no effect. Treatment with SP600125 also significantly
reduced AT-101-induced apoptosis (Fig. 5B). Moreover,
in U937 cells stably expressing the dominant negative
mutant of c-Jun, TAM-67, AT-101-induced apoptosis was
significantly reduced as compared to vector-only controls.
Taken together, these findings indicate a requirement for
SAPK/JNK signaling in AT-101-induced apoptosis.
Discussion
Overexpression of anti-apoptotic members of the Bcl-2
family is frequently observed in many different tumor
types and has been associated with resistance to radio-
and chemotherapy and poor prognosis. The identification
of gossypol as an orally available, potent small molecule
inhibitor of several anti-apoptotic members of the Bcl-2
family provides a rationally designed strategy to overcome
this resistance and improve clinical outcome. In the
present studies, we investigated the effect of AT-101 on
radiation-induced apoptosis in human U937 and Jurkat T
leukemic cells. We demonstrated that AT-101 strongly
enhanced radiation-induced apoptosis to levels that
exceeded additivity, as shown by isobolographic analysis.
Furthermore, activation of the SAPK/JNK pathway, which
is known to mediate radiation-induced apoptosis, was
found to play an important role in the cytotoxic effects of
AT-101.
Proteins of the Bcl-2 family mediate mitochondrial per-
meability and are therefore the key regulators of the
intrinsic apoptotic pathways [36]. Bcl-2 proteins contain
regions of amino acid sequence similarity, known as Bcl-
2 homology (BH) domains. The family consists of the
anti-apoptotic Bcl-2 group (such as Bcl-2, Bcl-XL, Mcl-1),
the pro-apoptotic Bax group (Bax, Bak and Bok) and the
pro-apoptotic BH3 domain-only group (including Bad,
Bid, Noxa, Puma). Bcl-2 family members can homo- and
heterodimerize. Dimerization and multimerization is
essential for their function. Under normal conditions,
BH3 domain-only proteins are either expressed at low lev-
els or remain inactive in the cytoplasm. In response to a
unique type of stress stimulus a BH3 domain-only protein
is activated and translocates to the mitochondria to exert
its pro-apoptotic effect. There are two models that
describe how BH3 domain-only proteins work [36].
AT-101 employs the SAPK/JNK pathway to induce apoptosisFigure 5
AT-101 employs the SAPK/JNK pathway to induce apoptosis. A: AT-101 (5 μM) induced SAPK/JNK in U937 and Jur-
kat T cells can be inhibited by the SP600125 kinase inhibitor; t = 90 min. B: Blockade of SAPK/JNK signaling by kinase inhibitor 
(SP600125) or dominant-negative c-Jun (TAM-67) inhibits AT-101 (5 μM)-induced apoptosis at t = 20 h in U937 cells. Data are 
presented as mean values (± SD) from 2 independent experiments. *p < 0.005, Student's t test.
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Radiation Oncology 2009, 4:47 http://www.ro-journal.com/content/4/1/47According to one model (the direct model), they tran-
siently interact with Bax and/or Bak to induce their homo-
multimerization forming a pore through which
cytochrome c and other apoptogenic mediators are
released. Inhibitory Bcl-2 family members can bind and
sequester BH3 domain-only molecules, thereby prevent-
ing their pro-apoptotic interaction with Bax or Bak.
According to another model, the indirect model, Bax and
Bak are complexed by inhibitory Bcl-2 family members.
BH3 domain-only members release Bax and Bak from
such inhibition by displacing them in the complex. In this
way, Bax or Bak are also free to form the homomultimer
and cause mitochondrial permeabilization.
Thus, the anti-apoptotic function of Bcl-XL/Bcl-2 is largely
attributed to their ability to interact with pro-apoptotic
members of the Bcl-2 family through the hydrophobic
BH3 binding α helix, thereby preventing Bax/Bak-medi-
ated release of cytochrome c. According to this mecha-
nism, small molecules that interact with the BH3 binding
α helix of Bcl-XL/Bcl-2 will function as Bcl-XL/Bcl-2 antag-
onists and promote apoptosis. In a search for such candi-
dates, the combination of computer modeling and in vitro
fluorescence polarization displacement studies demon-
strated a direct inhibition of the binding between a 16-res-
idue Bak BH3 peptide and Bcl-XL and Bcl-2 by gossypol
with IC50 values of 0.4 μM and 10 μM, respectively [21].
Moreover, in silico docking studies using the 3-dimen-
sional structure of Bcl-XL predicted gossypol to bind in the
deep hydrophobic groove on the surface of Bcl-XL that is
known to be the same site targeted by endogenous antag-
onists of this protein [15].
Gossypol has been shown to induce apoptosis in a variety
of tumor cell lines overexpressing Bcl-XL and/or Bcl-2
[15,16,18]. In addition, an antitumor effect was shown in
several cancer cell types [37-42]. Not many studies, how-
ever, have considered the cytotoxic effect of gossypol in
combination with radio- and/or chemotherapy. In the
human prostate cancer cell line PC-3, AT-101 potently
enhanced radiation-induced apoptosis and growth inhi-
bition and reduced clonogenic survival [22]. (±)-Gossypol
induced enhanced radiosensitivity, albeit with substantial
variation in a panel of carcinoma cell lines, which prima-
rily resulted from reduced double-strand break repair
capacity [43]. In lymphoma cells the addition of CHOP
chemotherapy significantly enhanced AT-101-induced
cytotoxicity [21].
In the present studies we show a dose- and time-depend-
ent induction of apoptosis by AT-101 in two human
leukemic cell lines. Consistent with the observation of
others [44,45], the (-) enantiomer was more potent in
inducing apoptosis than racemic gossypol as reflected by
the ED50 values. In addition, AT-101 strongly enhanced
radiation-induced apoptosis in a sequence-dependent
fashion. The type of interaction between both stimuli was
synergistic as demonstrated by isobolographic analysis
and a combination index smaller than 1.0. The nature of
this enhancing effect is unknown, but is clearly the result
of partially overlapping and, more importantly, partially
distinct mechanisms. Radiation is known to induce the
apoptotic cascade via the mitochondria-dependent intrin-
sic pathway where cytochrome c release is the critical
event leading to caspase activation. The major mode of
action of gossypol is through its interaction with the BH3-
binding groove in Bcl-XL and to a lesser extent in Bcl-2,
thereby preventing their interaction with pro-apoptotic
proteins and allowing mitochondrial permeabilization.
In addition, AT-101 has been found to bind to and inhibit
the anti-apoptotic function of Mcl-1 [46]. Gossypol may
also directly interact with pro-apoptotic Bcl-2 family
members (Bax, Bak) and promote their multimerization
which is essential for the release of cytochrome c [19].
Because gossypol has been reported to also increase radi-
osensitivity [22,43], we generated clonogenic survival
(data not shown) and cell viability curves, but could not
detect significant radiosensitization. This indicates that in
the cell systems used apoptosis is the prevailing mode of
cell death after the combination of radiation and AT-101.
Moreover, this short term cell kill could be fully inhibited
by the pan-caspase inhibitor Z-VAD.
Activation of SAPK/JNK has been shown to be essential
for apoptosis induction by many types of cellular stress,
including radiation and chemotherapeutic drugs
[27,47,48]. The SAPK/JNK pathway involves sequential
phosphorylation and activation of the proteins MAPK/
ERK kinase kinase 1, SAPK/ERK kinase 1, SAPK/JNK and
c-Jun. There are several observations by others that
prompted us to investigate the effect of gossypol on this
pro-apoptotic signaling system. First, because overexpres-
sion of one of the prime targets of gossypol, Bcl-XL, was
reported to inhibit SAPK/JNK [29], we reasoned that
blocking this (and other) anti-apoptotic protein, the pro-
death signaling would be restored. Second, it has been
shown that SAPK/JNK translocates to the mitochondria
upon irradiation and other stress factors where it phos-
phorylates and inactivates anti-apoptotic Bcl-2 family
members, including Bcl-2, Bcl-XL and Mcl-1 [49-51].
Finally, other investigators have recently shown that Bcl-2
antagonists like gossypol, can increase bortezomib-medi-
ated cellular stress and SAPK/JNK activation in lymphoma
cells [52]. We have previously shown that stimulation of
the SAPK/JNK pathway is essential for radiation-induced
apoptosis in both J16 and U937 cells [34,46]. In our
present studies, we found that in both leukemic cells and
squamous cell carcinoma gossypol rapidly activated the
SAPK/JNK pathway, notably with AT-101 being morePage 8 of 10
(page number not for citation purposes)
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vation of SAPK/JNK preceded the appearance of the typi-
cal morphological features of apoptosis, indicating a
temporal relation between both events. The pivotal role of
SAPK/JNK in AT-101-induced apoptosis was demon-
strated by our experiments using the SAPK/JNK inhibitor
SP600125 and the dominant-negative mutant of c-Jun.
This mutant, denominated TAM-67, lacks the N-terminal
transactivation domain of c-Jun, including Ser-63 and Ser-
73, the sites of phosphorylation and activation of the
SAPK/JNK pathway [31]. SP600125 significantly inhib-
ited AT-101-induced SAPK/JNK phosphorylation and
apoptosis induction. Moreover, in cells overexpressing the
TAM-67 mutant, AT-101-induced apoptosis was signifi-
cantly reduced. Collectively, these data suggest that not
only radiation-, but also AT-101-induced apoptosis
requires a functional SAPK/JNK signaling system.
Conclusion
In summary, we have demonstrated that AT-101 strongly
enhances radiation-induced apoptosis to supra-additive
levels. We present evidence that activation of the SAPK/
JNK pathway significantly contributes to the apoptotic
effect of AT-101. This combined approach represents an
attractive strategy to overcome treatment resistance due to
overexpression of anti-apoptotic Bcl-2 family members.
We are currently performing preclinical proof-of-principle
studies with this novel combined modality treatment in a
mouse xenograft tumor model.
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